Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors.
The last decade in oncology has been highlighted by the emergence of novel, highly specific anti-cancer agents, targeting a variety of molecular structures and able to inhibit aberrantly activated oncogenic pathways. Epidermal growth factor receptor inhibitors (EGFRIs) represent one type of such "targeted" agents. Their use made treatment more tolerable and resulted in significant reduction of systemic adverse effects. However, EGFRIs are associated with toxicities affecting the skin and adnexal structures, and mucosal surfaces that affect the majority of treated patients. Significant dermatologic toxicities have changed the role and involvement of dermatologists in their care. It is essential to be familiar with these adverse effects, potential complications, long-term sequelae, and available effective treatment strategies in order to appropriately manage these patients. This review will describe the clinical presentation, histopathology, underlying mechanisms, and management options, emphasizing evidence-based approaches.
Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Yevgeniy
Y
Balagula
Claus
C
Garbe
Patricia L
PL
Myskowski
Axel
A
Hauschild
Bernardo L
BL
Rapoport
Christine B
CB
Boers-Doets
Mario E
ME
Lacouture
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D008297:Male; D012867:Skin / Q000187:drug effects* / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D066246:ErbB Receptors